NCCN updates guidelines for high-grade prostate cancer

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

DNA/RNA material contained in circulating extracellular vesicles secreted into the bloodstream by tumor cells captures cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a new study.

July 26, 2024

Vol.50 No.30

Drugs & Targets

FDA accepts Telix’s NDA for prostate cancer imaging agent

FDA has accepted the filing of Telix Pharmaceuticals Limited’s New Drug Application for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer.

July 26, 2024

Vol.50 No.30

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

Nubeqa + androgen deprivation therapy improves rPFS for mHSPC in phase III trial

The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, research suggests, which could contribute to higher rates of aggressive prostate cancer in African American men.

July 19, 2024

Vol.50 No.29

Clinical Roundup

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.

July 19, 2024

Vol.50 No.29

NCCN updates guidelines for high-grade prostate cancer

YOU MAY BE INTERESTED IN

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

FDA accepts Telix’s NDA for prostate cancer imaging agent

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Nubeqa + androgen deprivation therapy improves rPFS for mHSPC in phase III trial

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Renew today!

Subscriber content

Login

NCCN updates guidelines for high-grade prostate cancer

YOU MAY BE INTERESTED IN

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

FDA accepts Telix’s NDA for prostate cancer imaging agent

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Nubeqa + androgen deprivation therapy improves rPFS for mHSPC in phase III trial

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”